p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53 -mutated acute myeloid leukemia and myelodysplastic syndromes
American Journal of Clinical Pathology · 2024
DOI: 10.1093/ajcp/aqae034 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2024. Verfasst von Nivaz Brar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, CA, US. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplasm, Residual, Myelodysplastic Syndromes, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
Measurable residual disease flow cytometry (MRD-FC) and molecular studies are the most sensitive methods for detecting residual malignant populations after therapy for TP53-mutated acute myeloid leukemia and myelodysplastic neoplasms (TP53+ AML/MDS). However, their sensitivity is limited in suboptimal aspirates or when the immunophenotype of the neoplastic blasts overlaps with erythroids or normal maturing myeloid cells. In this study, we set out to determine if p53 immunohistochemistry (IHC) correlates with MRD-FC and next-generation sequencing (NGS) in the posttherapy setting and to determine the utility of p53 IHC to detect residual disease in the setting of negative or equivocal MRD-FC.
Methods
We retrospectively identified 28 pre- and posttherapy bone marrow biopsy specimens from 9 patients with TP53+ AML/MDS and a p53 overexpressor phenotype by IHC (strong 3+ staining at initial diagnosis). Next-generation sequencing and/or MRD-FC results were collected for each specimen.
Results
Using a threshold of more than ten 2-3+ cells in any one 400× field, p53 IHC detected residual disease with a sensitivity of 94% and a specificity of 89%. The threshold used in this study showed a high degree of concordance among 6 blinded pathologists (Fleiss κ = 0.97).
Conclusions
Our study suggests that p53 IHC can be used as a rapid tool (within 24 hours) to aid in the detection of residual disease that may complement MRD-FC or NGS in cases in which the flow cytometry immunophenotype is equivocal and/or the bone marrow aspirate is suboptimal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University School of Medicine, Stanford, CA, US.
- Department of Medicine, Division of Hematology, Cancer Institute, Stanford, CA, US.
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, US.
ORCID-Profile: Nivaz Brar, Dita Gratzinger, Sebastian Fernandez-Pol
Zitieren
APA
Brar, N., Lawrence, L., Fung, E., Zehnder, J. L., Greenberg, P. L., Mannis, G. N., Zhang, T. Y., Gratzinger, D., Oak, J., Silva, O., Kurzer, J., Tan, B., Menke, J. R., & Fernandez-Pol, S. (2024). p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53 -mutated acute myeloid leukemia and myelodysplastic syndromes. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqae034
Vancouver
Brar N, Lawrence L, Fung E, Zehnder JL, Greenberg PL, Mannis GN, et al. p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53 -mutated acute myeloid leukemia and myelodysplastic syndromes. American Journal of Clinical Pathology. 2024. doi:10.1093/ajcp/aqae034
BibTeX
@article{Brar2024,
author = {Brar, Nivaz and Lawrence, Lauren and Fung, Eula and Zehnder, James L and Greenberg, Peter L and Mannis, Gabriel N and Zhang, Tian Y and Gratzinger, Dita and Oak, Jean and Silva, Oscar and Kurzer, Jason and Tan, Brent and Menke, Joshua R and Fernandez-Pol, Sebastian},
title = {p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53 -mutated acute myeloid leukemia and myelodysplastic syndromes},
journal = {American Journal of Clinical Pathology},
year = {2024},
doi = {10.1093/ajcp/aqae034}
}
EUVIMED